Context Therapeutics AI Stock Analysis
Want to see CNTX full AI Analyst Report?
Context Therapeutics (CNTX) AI Stock Analysis
Context Therapeutics
(NASDAQ:CNTX)
Overall score is held down primarily by weak financial performance (no revenue, rising losses, and ongoing cash burn) and bearish technicals (below key moving averages with negative MACD). A positive corporate update on early clinical data and trial progress provides some support, but it is not enough to offset the financial and trend headwinds.
Context Therapeutics (CNTX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $15.29M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.45M
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 0.89
- Revenue Growth
- ―
- EPS Growth
- -66.49%
- Country
- US
- Employees
- 15
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Context Therapeutics Business Overview & Revenue Model
Company Description
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated...
How the Company Makes Money
As a clinical-stage biotechnology company, Context Therapeutics does not have a broadly disclosed, product-based commercial revenue model in publicly available information; therefore, specific recurring revenue streams from product sales are null. Th...
Context Therapeutics Financial Statement Overview
Summary
Financial profile remains weak: no revenue, widening net losses (TTM about -$43.9M), and persistent negative operating/free cash flow (TTM about -$34.0M) imply ongoing funding needs. The key offset is very low leverage (debt-to-equity near zero), but equity has been shrinking, reflecting cumulative losses and burn.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -43.83M | -36.11M | -26.71M | -23.95M | -14.87M | -10.53M |
| Net Income | -43.89M | -36.12M | -26.73M | -23.96M | -14.84M | -10.46M |
Balance Sheet | ||||||
| Total Assets | 36.54M | 68.49M | 98.13M | 16.06M | 37.97M | 51.31M |
| Cash, Cash Equivalents and Short-Term Investments | 34.41M | 66.00M | 94.43M | 14.45M | 35.50M | 49.64M |
| Total Debt | 206.52K | 112.06K | 219.38K | 0 | 55.08K | 0 |
| Total Liabilities | 5.53M | 8.02M | 2.86M | 4.19M | 3.21M | 3.03M |
| Stockholders Equity | 31.01M | 60.47M | 95.27M | 11.87M | 34.76M | 48.27M |
Cash Flow | ||||||
| Free Cash Flow | -34.03M | -26.42M | -29.31M | -21.05M | -14.09M | -9.05M |
| Operating Cash Flow | -33.97M | -26.39M | -14.56M | -21.05M | -13.55M | -8.80M |
| Investing Cash Flow | -8.56M | -2.03M | -14.76M | 0 | -536.84K | -250.00K |
| Financing Cash Flow | 0 | -15.27K | 109.29M | 0 | -102.07K | 58.39M |
Context Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTX, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.27, and below the 200-day MA of 1.34, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 33.69 is Neutral, neither overbought nor oversold. The STOCH value of 20.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNTX.
Context Therapeutics Risk Analysis
Context Therapeutics disclosed 63 risk factors in its most recent earnings report. Context Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksContext Therapeutics Peers Comparison
Overall Rating
CNTX45Neutral
ADAG40Underperform
WHWK40Underperform
ANEB33Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $15.29M | -0.36 | -96.54% | ― | ― | -66.49% | |
| 40Underperform | $122.20M | -3.86 | -29.09% | ― | 8906.15% | 41.48% | |
| 40Underperform | $184.70M | -2.87 | -55.66% | ― | -100.00% | -825.52% | |
| 33Underperform | $11.42M | -1.82 | -64.46% | ― | ― | 33.15% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CNTX | Context Therapeutics, Inc. | 0.17 | -0.97 | -85.44% | |
| WHWK | Whitehawk Therapeutics, Inc. | 3.13 | 1.14 | 57.29% | |
| ADAG | Adagene, Inc. | 1.82 | 0.05 | 2.82% | |
| ANEB | Anebulo Pharmaceuticals, Inc. | 0.28 | -2.01 | -87.77% |
Context Therapeutics Corporate Events
Context Therapeutics Reports Q3 Results and CTIM-76 Trial Progress
PositiveOn November 10, 2026, Context Therapeutics reported third-quarter results and pipeline updates. In its Phase 1 CTIM-76 trial, nine efficacy-evaluable platinum-resistant ovarian cancer patients receiving biologically active weekly doses had a 22% conf...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
